Advertisement

Autoimmune Overlap Syndromes

  • Philippe J. ZamorEmail author
Chapter
  • 24 Downloads

Abstract

Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are autoimmune diseases of the liver. AIH has two major variants in which the features of classic AIH can coexist with either PBC, (formerly known as primary biliary cirrhosis) and PSC. AIH-PBC overlap syndrome (OS) occurs far more commonly than AIH-PSC OS. The recognition of these overlap syndromes mainly comes into significance because of lack of response to conventional corticosteroid therapy for AIH. Careful use of clinical and histologic criteria may be necessary for diagnosis. The overlap syndromes can progress to cirrhosis and liver failure if not recognized and adequately treated. Standard guidelines for treatment of these overlap syndromes are lacking, and is considered empiric and extrapolated from data derived from the primary autoimmune liver diseases.

Keywords

Overlap syndrome Primary biliary cholangitis Primary sclerosing cholangitis Cholangiogram AMA 

References

  1. 1.
    Beuers U, et al. Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’. Hepatology. 2015;62(5):1620–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Bunchomtavakul CK, Reddy R. Diagnosis and management of overlap syndromes. Clin Liver Dis. 2015;19:81–97.CrossRefGoogle Scholar
  3. 3.
    Zhao L, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011;6(4):e18909.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Longhi MS, et al. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells. Hepatology. 2009;50(1):130–42.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Longhi MS, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology. 2007;46(2):472–84.PubMedCrossRefGoogle Scholar
  6. 6.
    Longhi MS, et al. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis. Hepatology. 2008;47(2):581–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Vergani D, et al. Immunoglobulin on the surface of isolated hepatocytes is associated with antibody-dependent cell-mediated cytotoxicity and liver damage. Liver. 1987;7(6):307–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Mayo MJ, et al. The relationship between hepatic immunoglobulin production and CD154 expression in chronic liver diseases. Liver Int. 2006;26(2):187–96.PubMedCrossRefGoogle Scholar
  9. 9.
    Jensen DM, et al. Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med. 1978;299(1):1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Ma Y, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology. 2002;35(3):658–64.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Wen L, et al. T-cell-directed hepatocyte damage in autoimmune chronic active hepatitis. Lancet. 1990;336(8730):1527–30.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Manns MP, Vergani D. Autoimmune hepatitis. Semin Liver Dis. 2009;29(3):239–40.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Liston A, et al. Gene dosage--limiting role of Aire in thymic expression, clonal deletion, and organ-specific autoimmunity. J Exp Med. 2004;200(8):1015–26.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Donaldson PT. Genetics of liver disease: immunogenetics and disease pathogenesis. Gut. 2004;53(4):599–608.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Oliveira LC, et al. Autoimmune hepatitis, HLA and extended haplotypes. Autoimmun Rev. 2011;10(4):189–93.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Lucena MI, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338–47.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Singh G, et al. Autoimmune hepatitis triggered by hepatitis A. Gut. 2007;56(2):304.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Lenzi M, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut. 1999;45(3):435–41.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Gregorio GV, et al. Mimicry between the hepatitis B virus DNA polymerase and the antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis B virus infection. J Immunol. 1999;162(3):1802–10.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Gregorio GV, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol. 2003;133(3):404–13.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Holdener M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205(6):1409–22.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Vergani D, et al. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med. 1980;303(2):66–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56(4):958–76.PubMedCrossRefGoogle Scholar
  24. 24.
    Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Kloppel G, et al. Histopathological features in mixed types of chronic aggressive hepatitis and primary biliary cirrhosis. Correlations of liver histology with mitochondrial antibodies of different specificity. Virchows Arch A Pathol Anat Histol. 1977;373(2):143–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Qiu F, et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis. Nat Commun. 2017;8:14828.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Lazaridis KN, et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology. 2007;46(3):785–92.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Chazouilleres O, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998;28(2):296–301.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Heurgue A, et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol Clin Biol. 2007;31(1):17–25.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Vierling JM. Autoimmune hepatitis and overlap syndromes: diagnosis and management. Clin Gastroenterol Hepatol. 2015;13(12):2088–108.PubMedCrossRefGoogle Scholar
  31. 31.
    Verdonk RC, et al. Bile ductal injury and ductular reaction are frequent phenomena with different significance in autoimmune hepatitis. Liver Int. 2016;36(9):1362–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):318–28.PubMedCrossRefGoogle Scholar
  33. 33.
    Levy C, et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol. 2014;12(8):1398–405.PubMedCrossRefGoogle Scholar
  34. 34.
    Lohse AW, et al. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals. Hepatology. 1999;29(4):1078–84.PubMedCrossRefGoogle Scholar
  35. 35.
    Boberg KM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54(2):374–85.PubMedCrossRefGoogle Scholar
  36. 36.
    Lindor KD, et al. Primary biliary cirrhosis. Hepatology. 2009;50(1):291–308.PubMedCrossRefGoogle Scholar
  37. 37.
    Invernizzi P, Lleo A, Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis. 2007;27(2):161–72.PubMedCrossRefGoogle Scholar
  38. 38.
    Invernizzi P, et al. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis. 2005;25(3):298–310.PubMedCrossRefGoogle Scholar
  39. 39.
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72.CrossRefGoogle Scholar
  40. 40.
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51(2):237–67.CrossRefGoogle Scholar
  41. 41.
    Vergani D, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41(4):677–83.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Metcalf JV, et al. Natural history of early primary biliary cirrhosis. Lancet. 1996;348(9039):1399–402.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Nguyen HH, et al. Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS). PLoS One. 2018;13(3):e0193960.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Czaja AJ. Cholestatic phenotypes of autoimmune hepatitis. Clin Gastroenterol Hepatol. 2014;12(9):1430–8.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Lindgren S, et al. Transitions between variant forms of primary biliary cirrhosis during long-term follow-up. Eur J Intern Med. 2009;20(4):398–402.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Poupon R, et al. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology. 2006;44(1):85–90.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Efe C, et al. Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol. 2014;26(5):532–7.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Neuhauser M, et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis. Am J Gastroenterol. 2010;105(2):345–53.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Yang F, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol. 2016;50(1):114–23.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Silveira MG, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol. 2007;102(6):1244–50.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Joshi S, et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology. 2002;35(2):409–13.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Roll J, et al. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983;308(1):1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Summerfield JA, et al. The biliary system in primary biliary cirrhosis. A study by endoscopic retrograde cholangiopancreatography. Gastroenterology. 1976;70(2):240–3.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Carrion AF, Rosen JD, Levy C. Understanding and treating pruritus in primary biliary cholangitis. Clin Liver Dis. 2018;22(3):517–32.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Datta DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50(3):323–32.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kremer AE, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391–400.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94(2):488–93.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Podesta A, et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci. 1991;36(2):216–20.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut. 2002;50(3):436–9.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Jones EA, Neuberger J, Bergasa NV. Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM. 2002;95(8):547–52.PubMedCrossRefGoogle Scholar
  61. 61.
    Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98(12):2736–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Mayo MJ, et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666–74.PubMedCrossRefGoogle Scholar
  63. 63.
    Cauch-Dudek K, et al. Fatigue in primary biliary cirrhosis. Gut. 1998;43(5):705–10.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Huet PM, et al. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis. Am J Gastroenterol. 2000;95(3):760–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Goldblatt J, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology. 2002;122(5):1235–41.PubMedCrossRefGoogle Scholar
  66. 66.
    Watt FE, James OF, Jones DE. Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM. 2004;97(7):397–406.CrossRefPubMedGoogle Scholar
  67. 67.
    Mang FW, et al. Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia. 1997;12(3):167–70.PubMedCrossRefGoogle Scholar
  68. 68.
    Vivino FB, et al. Sjogren’s syndrome: an update on disease pathogenesis, clinical manifestations and treatment. Clin Immunol. 2019;203:81–121.PubMedCrossRefGoogle Scholar
  69. 69.
    Marshall LL, Stevens GA. Management of Primary Sjogren’s syndrome. Consult Pharm. 2018;33(12):691–701.PubMedCrossRefGoogle Scholar
  70. 70.
    Gregorio GV, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544–53.PubMedCrossRefGoogle Scholar
  71. 71.
    McNair AN, et al. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in five cases. Am J Gastroenterol. 1998;93(5):777–84.PubMedCrossRefGoogle Scholar
  72. 72.
    van Buuren HR, et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol. 2000;33(4):543–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Floreani A, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol. 2005;100(7):1516–22.PubMedCrossRefGoogle Scholar
  74. 74.
    Abdo AA, et al. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology. 2002;36(6):1393–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Trivedi PJ, Hirschfield GM. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther. 2012;36(6):517–33.PubMedCrossRefGoogle Scholar
  76. 76.
    Chapman RW, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut. 1980;21(10):870–7.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Czaja AJ. The variant forms of autoimmune hepatitis. Ann Intern Med. 1996;125(7):588–98.PubMedCrossRefGoogle Scholar
  78. 78.
    Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol. 1992;14(2–3):325–31.PubMedCrossRefGoogle Scholar
  79. 79.
    Schrumpf E, et al. Hepatobiliary complications of inflammatory bowel disease. Semin Liver Dis. 1988;8(3):201–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14(3):331–7.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998;28(2):360–5.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Hunter M, et al. Evaluating distinctive features for early diagnosis of primary sclerosing cholangitis overlap syndrome in adults with autoimmune hepatitis. Ulster Med J. 2011;80(1):15–8.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Dienes HP, et al. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis. 2002;6(2):349–62, vi.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Olsson R, et al. High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med. 2009;20(2):190–6.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Gheorghe L, et al. Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease. Eur J Gastroenterol Hepatol. 2004;16(6):585–92.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol. 2000;33(4):537–42.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Broome U, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38(4):610–5.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol. 2010;16(8):934–47.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    European Society of Gastrointestinal Endoscopy, European Association for the Study of the Liver. Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. J Hepatol. 2017;66(6):1265–81.CrossRefGoogle Scholar
  90. 90.
    Lindor KD, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–14.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Chapman R, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51(2):660–78.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Ilyas JA, O’Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011;25(6):765–82.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Schramm C, et al. Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. Liver Transpl. 2010;16(4):461–9.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Tanaka T, Sugawara Y, Kokudo N. Liver transplantation and autoimmune hepatitis. Intractable Rare Dis Res. 2015;4(1):33–8.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Bhanji RA, et al. Liver transplantation for overlap syndromes of autoimmune liver diseases. Liver Int. 2013;33(2):210–9.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Yamashiki N, et al. Living-donor liver transplantation for autoimmune hepatitis and autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. Hepatol Res. 2012;42(10):1016–23.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of HepatologyCarolinas Medical Center-Atrium HealthCharlotteUSA

Personalised recommendations